AI-first biotechnology company using computational models to discover and develop first-in-class small-molecule therapeutics
AI-first biotechnology company using computational models to discover and develop first-in-class small-molecule therapeutics. Its pipeline targets conserved biological choke points across infectious disease, oncology, inflammation, fibrosis, immunology, and other indications. Lead programs include MDL-001, a broad-spectrum antiviral, and MDL-4102, a BRD4 inhibitor.